A Phase 1 interventional study of H-Coil Deep TMS and SHAM Coil TMS in Mild Cognitive Impairment, sponsored by Brainsway. Status unknown at 1 site in Israel. Open to participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-07-14.
Sponsored by Brainsway · Phase 1, Interventional, and Other
This is a first feasibility study in order to test if deep Transcranial Magnetic Stimulation (TMS) treatment with high frequency (10Hz) will improve the symptoms of patient MCI (Mild Cognitive impairment). The hypothesis of the study is that high frequency treatment with deep TMS will improve the daily functioning of patients who suffers from MCI.
3,843 studies on the registry are indexed under Cognitive Dysfunction; 1,100 are open to participants now.
This study's planned enrollment of 30 is below the median of 65 across 2,808 interventional studies indexed under Cognitive Dysfunction.
Browse Cognitive Dysfunction studies →Brainsway is the lead sponsor of 21 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
this group will receive high frequency deep TMS treatment of 10HZ
Device: H-Coil Deep TMS
this group will receive SHAM treatment of deep TMS
Device: SHAM Coil TMS
this group will receive high frequency treatment of deep TMS with 10Hz
this group will receive SHAM treatment of deep TMS
Mindstreams
Mindstreams test is designed to test the I.Q change of the patients from baseline
Time frame: the test will be assessed on visit 17 which means 4 month from baseline
CDR - Clinical Dementia Rating
CDR test is designed to test the dementia severity of the patients from baseline
Time frame: the test will be assessed on visit 17 which means 4 month from baseline
This study is status unknown, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brainsway